CME Quiz

Continuing Medical Education Accreditation

AMA PRA Category 1 credits

The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2.5 ^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Instructions

After reading "Clinical Update on Oncology Treatments and Trends," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program.

1. For what clinical indication has the US Food and Drug Administration (FDA) approved the use of erlotinib?

• With combination chemotherapy for colorectal cancer.
• As a single agent for locally advanced or metastatic NSCLC.

2. A study begun at Vanderbilt University in 2001 found highly favorable results in the treatment of advanced untreated or metastatic NSCLC with a regimen consisting of:

• Bevacizumab, docetaxel, and cisplatin.
• Bevacizumab, paclitaxel, and carboplatin.

3. What proportion of lung cancers have metastasized by the time they are detected?

• 60%
• 90%

4. The survival rate found with the use of spiral computed tomography in screening for lung cancer in the International Early Lung Cancer Project has been better than:

• 65%
• 50%

5. An issue of debate in adjuvant therapy for colorectal cancer has been:

• Whether it benefits patients with stage III disease as much as those with stage II disease.
• Whether it is applicable to patients who have undergone adjunctive radiotherapy.

6. Phase 2 and 3 clinical studies have clearly shown that adding which of the following drugs to a first-line regimen of 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer improves survival over that with 5-FU and LV alone?

• Cyclophosphamide
• Docetaxel

7. Which of the following laboratory techniques are used in determining human epidermal growth factor receptor 2 overexpressing breast carcinomas for treatment with trastuzumab?

• Enzyme immunoassay
• Western blotting

8. The combined data from National Surgical Adjuvant Breast and Bowel Project trial B-31 and North Central Treatment Group trial N9831 found that adding trastuzumab to chemotherapy in the adjuvant treatment of breast cancer produced an absolute gain of which of the following percentages in disease-free survival at 3 years?

• 12%
• 42%

9. The type of non-Hodgkin's lymphoma that has shown the most significant increase in older persons is:

• Follicular lymphoma
• T-cell lymphoma

10. For nearly a quarter century the gold standard for treating diffuse large-cell lymphoma was a combination of drugs known as CHOP, named for the Children's Hospital of Philadelphia, where the regimen was developed. The combination of drugs includes:

• Rituximab, vincristine, and prednisone
• Anthracyclines vincristine, prednisone

GOAL

To provide participants with a clinical update on treatments for lung, colorectal, and breast cancers, and lymphoproliferative disorders.

TARGET AUDIENCE

This activity is intended for primary care physicians, oncologists, medical directors, and other managed care decision makers.

LEARNING OBJECTIVES

After participating in this activity, participants should be better able to:

• Discuss how adjuvant chemotherapeutic regimens are being used to treat breast and other forms of cancer.

CONTINUING MEDICAL EDUCATION ACCREDITATION

AMA PRA Category 1 credits

The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2.5 Ô. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Release Date: March 31, 2006. Expiration Date: March 31, 2007.

FUNDING

This program is supported by an educational grant from Genentech.

---

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Download PDF: CME Quiz